华熙生物(688363.SH)与巨子生物(02367.HK)“开战”以来,双方已拉锯多个回合。从巨子生物最新声明来看,这场“成分之战”暴露了重组胶原蛋白行业检测方法有待优化等事实。6月23日晚,巨子生物再次发表声明,坦言“公司现有的质量标准、检测方法以及标签标识在某些方面已逐渐显示出其局限性”,并明确表示“下一步将联合科研机构加速推进化妆品中重组胶原蛋白定性定量检测方法的优化与验证”。谁在说谎?...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.